Oric Pharmaceuticals (NASDAQ:ORIC) Receives “Buy” Rating from HC Wainwright

Oric Pharmaceuticals (NASDAQ:ORIC)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 234.67% from the company’s previous close.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Citigroup lifted their price objective on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Wells Fargo & Company boosted their target price on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Finally, Piper Sandler began coverage on Oric Pharmaceuticals in a research note on Wednesday, January 7th. They set an “overweight” rating and a $22.00 price target for the company. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.90.

Oric Pharmaceuticals Stock Performance

NASDAQ:ORIC opened at $7.47 on Thursday. Oric Pharmaceuticals has a 1 year low of $3.90 and a 1 year high of $14.93. The stock has a market cap of $749.67 million, a P/E ratio of -4.91 and a beta of 1.36. The stock has a 50-day simple moving average of $11.62 and a 200-day simple moving average of $11.31.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. On average, equities research analysts predict that Oric Pharmaceuticals will post -2.17 EPS for the current year.

Insider Activity at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the sale, the chief financial officer directly owned 68,148 shares in the company, valued at approximately $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.82% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vivo Capital LLC grew its position in Oric Pharmaceuticals by 50.3% during the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock valued at $31,735,000 after purchasing an additional 1,046,154 shares in the last quarter. JPMorgan Chase & Co. increased its position in Oric Pharmaceuticals by 3,646.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares during the period. Royce & Associates LP raised its stake in Oric Pharmaceuticals by 521.2% during the 3rd quarter. Royce & Associates LP now owns 1,458,483 shares of the company’s stock valued at $17,502,000 after purchasing an additional 1,223,709 shares during the last quarter. Alkeon Capital Management LLC raised its holdings in Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock valued at $45,717,000 after acquiring an additional 500,000 shares in the last quarter. Finally, Resolute Capital Asset Partners LLC bought a new position in shares of Oric Pharmaceuticals during the 2nd quarter worth about $2,309,000. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals News Summary

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: ORIC selected a recommended Phase 3 dose (rinzimetostat 400 mg once daily) for the Himalayas‑1 global registrational trial in post‑abiraterone mCRPC and said the Phase 3 is expected to start in 1H 2026 — a clear program advancement toward a potential commercial pathway. ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D…
• Positive Sentiment: Multiple outlets note ORIC is advancing its prostate cancer candidate into Phase III, which de-risks the development pathway relative to earlier stages. Oric to advance prostate cancer drug to Phase III trials
• Neutral Sentiment: Wedbush trimmed its price target from $20 to $17 but kept an Outperform rating — an endorsement of long‑term potential, albeit with a more cautious near‑term valuation. Benzinga
• Negative Sentiment: Investors reacted to safety and side‑effect signals in the Phase 1b combination (rinzimetostat + darolutamide) — reports highlighted tolerability issues at higher doses that complicate dose selection and risk/regulatory discussions. Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
• Negative Sentiment: Coverage and headlines emphasizing side‑effect data and an after‑hours tumble amplified selling pressure as the market digests whether the safety profile will limit dosing or commercial advantage. Oric Pharmaceuticals Shares Fall on Side Effect Data in Prostate Cancer Drug Trial
• Negative Sentiment: Analyst/market commentary framed the update as unfavorable to current valuation levels, increasing near‑term downside risk until clearer safety/efficacy readouts and Phase 3 design clarity arrive. ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.